drugset / Trial / NCT02222441

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT02222441

Phase 1 Completed 14 enrolled Pfizer
Non-randomizedCrossoverOpen-labelBasic science

Summary

This study is designed to evaluate the potential effect of the moderate CYP3A inducer modafinil and the weak CYP3A inducer pioglitazone on the pharmacokinetics of palbociclib.

Timeline

Start
2014-10
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Modafinil Small molecule 400 mg
Subject Palbociclib Small molecule 125 mg Oral
Subject Pioglitazone Small molecule 45 mg

Indications

No indication recorded.